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STUDY PROTOCOL

Behavioural support and nicotine
replacement therapy for smokeless
tobacco cessation: protocol for a pilot
randomised‑controlled multi‑country trial
Faraz Siddiqui1, Linda Bauld2* , Ray Croucher1, Cath Jackson1,3, Ian Kellar4, Mona Kanaan1, Subhash Pokhrel5,
Rumana Huque6, Romaina Iqbal7, Javaid Ahmed Khan7, Ravi Mehrotra1,8, Kamran Siddiqi1 and on behalf of the
ASTRA Global Health Research Group

Abstract
Background: Smokeless tobacco (ST) is consumed globally by more than 350 million people, with approximately
85% of all users based in South and Southeast Asia. In this region, ST products are cheap and easily accessible.
Evidence-based interventions to people quit ST use are lacking. This study aims to test the feasibility of conducting a
future definitive trial of ST cessation, using a culturally adapted behavioural intervention, and/or nicotine replacement
therapy (NRT) in three South Asian countries.
Methods: We will conduct a factorial design, randomised-controlled pilot trial in Bangladesh, India and Pakistan.
Daily ST users will be recruited from primary health care settings in Dhaka, Noida and Karachi. Participants will be
individually randomised to receive intervention A (4 or 6 mg NRT chewing gum for 8-weeks), intervention B (BISCA:
face-to-face behavioural support for ST cessation), a combination of interventions A and B or usual care (Very Brief
Advice - VBA). The participants will provide demographic and ST use related data at baseline, and at 6, 12 and 26
weeks of follow-up. Salivary cotinine samples will be collected at baseline and 26 weeks. The analyses will undertake
an assessment of the feasibility of recruitment, randomisation, data collection and participant retention, as well as the
feasibility of intervention delivery. We will also identify potential cessation outcomes to inform the main trial, understand the implementation, context and mechanisms of impact through a process evaluation and, thirdly, establish
health resource use and impact on the quality of life through health economic data.
Discussion: The widespread and continued use of ST products in South Asia is consistent with a high rate of associated diseases and negative impact on the quality of life. The identification of feasible, effective and cost-effective
interventions for ST is necessary to inform national and regional efforts to reduce ST use at the population level. The
findings of this pilot trial will inform the development of larger trials for ST cessation among South Asian users, with
relevance to wider regions and populations having high rates of ST use.
Trial registration: ISRCTN identifier 65109397
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Introduction
Smokeless tobacco (ST) refers to a heterogeneous group
of tobacco-containing products that are non-combustible and consumed either orally or by inhalation
through the nose [1]. While ST is consumed by more
than 350 million individuals worldwide, approximately
85% of users are concentrated in South and South-East
Asia [2]. In these low-resource settings where ST is culturally ingrained, it remains cheap, widely available and
poorly regulated [3]. These South and South-East Asian
ST products often contain stimulants and flavourings
that enhance flavour and addictiveness. On the other
hand, their preparation methods induce high levels of
free nicotine, Tobacco Specific Nitrosamines (TSNAs)
and heavy metals [4]. Due to their composition, South
and South-East Asian ST products are highly addictive and toxigenic. Their continued use results in oral
and oropharyngeal cancers [5], rates of which are the
highest in South Asia [6]. ST use in these populations is
also linked to ischemic heart disease [7], as well as preterm delivery, stillbirth and low birth weight deliveries
[8]. In an effort to reduce the impact of ST use in South
Asian populations, the ASTRA Global Health Research
group [9] was formed in 2018. This group is conducting
a range of studies (focusing on cessation, youth, policy
and economics) to understand and address ST use in
South Asian settings.
The need for evidence-based guidelines and treatment for tobacco dependence is supported by Article 14 of the World Health Organization’s Framework
Convention for Tobacco Control (WHO-FCTC)
[10]. Tobacco cessation is also included in WHO’s
MPOWER approach, which is a set of six high impact
policy measures for reducing tobacco use [11]. In the
South Asian context, however, evidence and support
for ST cessation remain low. The Global Adult Tobacco
Survey (GATS) reports that only 31-57% of ST users in
South Asia are advised to quit ST by their health care
providers [12]. There is also a lack of evidence for effective and cost-effective interventions to support quit
attempts in these individuals. To date, two trials have
been conducted in South Asian settings, both in India.
The first study was a RCT of varenicline which did not
demonstrate any difference in biochemically verified
abstinence to ST at 12 weeks when compared to a placebo or reduce the risk for a lapse [13]. The other trial
was a cluster RCT of yogic breathing exercises which
were delivered through community outreach. The intervention was found to have a small, yet significant effect

on cessation rates at 6 months. This trial, however, had
limited implications for ST users as it included smokers
and dual users of smoking and ST products [14].
The use of behavioural interventions (counselling
from a trained adviser, or ‘behavioural support’) has
previously demonstrated effectiveness in achieving
abstinence among ST users [15]. This evidence base
builds upon studies of ST users conducted in Europe
and North America. The potential of behavioural interventions to support ST cessation remains largely unexplored in South Asian populations. The potential of
behavioural support may further be enhanced with the
use of pharmacotherapy such as nicotine replacement
therapy (NRT) which can reduce withdrawal symptoms
in individuals trying to quit [16]. In a multi-centre, prospective cohort study of South Asian ST users in England, NRT use was reported to be acceptable by ST
users receiving cessation support and was associated
with higher abstinence at 4 weeks when given alongside
a behavioural intervention, as compared to the behavioural intervention alone [17]. It is expected that similar
uptake and outcomes may be observed in South Asia. A
theory-based intervention ‘Behavioural support Intervention for ST Cessation in South Asian communities’
(BISCA) has previously been developed and tested in a
small number of ST users in the UK and Pakistan [18]
but has not been evaluated in a RCT or in wider South
Asian settings. Establishing an evidence base for BISCA
and NRT (separately and in combination) in this pilot
randomised study will provide a strong foundation for
a future definitive randomised trial of interventions for
South Asian ST users and support wider efforts in this
area.
Aims and objectives

We aim to conduct a pilot randomised controlled trial
of BISCA and NRT (individually and in combination)
to inform the design and implementation of a future
definitive trial for ST cessation in South Asian resident
populations.
Our primary objectives are to analyse and report data
on recruitment, randomisation and retention, data collection and intervention delivery. Our secondary outcomes are identification of potential cessation outcomes
for the main trial, an assessment of implementation, context and mechanisms of action through a process evaluation, and establishing health resource use and impacts on
the quality of life using health economics data.
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Methods
The protocol for the pilot RCT (v1.2) is registered with
the ISRCTN registry (65109397). The protocol manuscript confirms to items recommended in the SPIRIT
checklist and CONSORT statement extension for pilot
trials [19].
Trial design

We will conduct a pragmatic, individually randomised
multi-country pilot RCT of BISCA and NRT. A preliminary economic assessment and process evaluation
will be incorporated. The feasibility trial will use a 2×2
factorial design (Table 1) incorporating the following
interventions:
1. Intervention A (4 or 6 mg NRT chewing gum for 8
weeks)
2. Intervention B (BISCA: face-to-face behavioural support for South Asian ST cessation)
3. A combination of Interventions A and B
4. Usual care (VBA).
The factorial design is generally considered to be more
efficient than parallel arm trials, as it allows the simultaneous investigation of the effects of two or more treatments, as well as the effects of both in combination [20].
Study settings

This pilot trial will be conducted in Bangladesh, India
and Pakistan which are the three South Asian countries
with the highest regional prevalence of ST use. It will be
conducted in an urban setting in one administrative site
per country. Trial settings have been identified based on
the availability of research infrastructure and the local
prevalence of ST use. Settings meeting these criteria were
identified in Mirpur and Pallabi areas located in Dhaka
(Bangladesh), the Essa Nagri Union Council in Karachi
(Pakistan), and in Noida, adjacent to Delhi (India). All

settings are predominantly low-resource settings with a
high population density.
Study participants and eligibility criteria

The trial aims to recruit adult, exclusive users of ST products who are interested in making a quit attempt. We will
screen individuals to identify individuals who (i) use ST
products on a daily basis, (ii) are aged 18 years or above,
(iii) able to provide informed consent and (iv) motivated
and willing to quit ST in the next month. We define daily
use as self-reported ST use on at least 25 days in a month
over the past 6 months [21].
We will exclude (i) dual tobacco users who either selfreport combustible tobacco product use (cigarettes, bidis,
hookah) in the past month, or those having a carbon
monoxide (CO) level greater than 10ppm on a breath test
[22], measured using the Bedfont piCO™ smokerlyzer,
(ii) individuals who are currently receiving treatment for
tobacco cessation, (iii) individuals whose circumstances
might contra-indicate NRT use, such as pregnancy and/
or breastfeeding women, and (iv) those reporting unstable episodes of angina pectoris or myocardial infarction
or stroke in the past 3 weeks [23].
Details of interventions

As described above, the trial participants will receive
Nicotine replacement therapy (Intervention A) or BISCA
(Intervention B), either alone or in combination. The participants not randomised to receive these interventions
will receive usual care in the form of VBA [24] offered
by a trained cessation advisor. The VBA will last approximately 1–1.5 min. It incorporates the 3As approach
(Ask, Advise, Act) previously used for delivering smoking cessation in healthcare settings [24]. During this
brief interaction, the advisor will (i) ask about the type
of ST product consumed, (ii) identify ST related harms
and advise on stopping its use and (iii) act by providing
a self-help leaflet to prompt quit planning. Participants

Table 1 Schematic diagram for 2×2 factorial trial of interventions A (NRT) and B (BISCA)
Intervention A
NRT (8 weeks, 4/6 mg)
Intervention B - BISCA

Negative

Positive

Negative

No intervention
VBA + self-help material
Trial arm 1

Intervention A only
8-week NRT in addition to standard VBA + self-help material in
arm 1
Trial arm 2

Positive

Intervention B only
Behavioural support intervention for ST cessationBISCA (incorporates VBA and self-help)
Trial arm 3

Interventions A and B
Trial arm 4

BISCA behavioural support intervention for smokeless tobacco cessation in adults, ST smokeless tobacco, VBA very brief advice, NRT nicotine replacement therapy
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Fig. 1 The BISCA logic model identifying potential mechanisms of action (MoAs) and their underlying behaviour change techniques (BCTs)—MoAs
are identified in bold text in each box, with related BCTs listed underneath

receiving VBA will have no further interactions with the
cessation advisor. VBA will also be offered to other ST
using individuals who are either ineligible for trial participation or those who do not provide informed consent.
Details of interventions A and B are provided in further
detail below:
Intervention A: Nicotine replacement therapy

NRT will be provided to trial participants alongside VBA
and the self-help leaflet (described above). Following randomisation, the participants will undertake an 8-week
course of NRT chewing gum (Nicorette or its generic
equivalent, as per availability in each country); they will
receive either 4mg or 6 mg NRT supplies depending on
their baseline assessment. A cessation advisor will assess
each participant’s tobacco use through two items of the
heaviness of Tobacco Use Index [25]: (i) time to first ST
use and (ii) average number of daily ST intakes (chews/
dips). All participants will receive a standard 4mg dose;
however, those who report their first ST intake within
30 min of waking, or consuming ST >10 times/day) will
receive a 6-mg dose. The 6-mg dose will be given as a
combination of 4-mg and 2-mg nicotine chewing gums
taken together.
NRT will be provided by the cessation advisor at the
time of recruitment. The participants will be instructed
to start using NRT on an hourly basis, up to 15 doses
in a day starting from their planned quit date. The first
dose will be taken within the hour of waking or as soon
as craving develops. They will be instructed to perform the ‘park and chew’ method [26], which involves

chewing the gum until a peppery or flavoured taste
emerges, ‘parking’ it between cheek and gum to facilitate nicotine absorption through the oral mucosa for
approximately 30 min or until taste dissipates. A leaflet
providing this information in written form will also be
provided.
All participants will be provided with an initial 2-week
NRT supply following randomisation; subsequent two
weekly supplies of NRT will be provided by a trained
research officer to participants who report and demonstrate consumption of NRT on at least 5 days in the
previous week. Any adjustments to participants’ NRT
dosing, if necessary, will be made in light of participants’
experiences in the first week of its use. Where available,
participants will be provided the option to choose alternate NRT flavours in order to maximise their adherence
to treatment.
Intervention B: BISCA

BISCA is a face-to-face behavioural support intervention that will be provided to trial participants. BISCA
is a theory-based, culturally modified intervention that
has previously been developed and tested among South
Asian ST users in the UK and Pakistan, and adapted
for wider testing in Bangladesh, India and Pakistan.
BISCA comprises a set of 23 activities that target evidence-based behaviour change techniques (BCTs) that
attempt to change ST behaviour through modifying
the underlying mechanisms of action (MoA’s) (Fig. 1,
BISCA causal model). Intervention resources consist
of an advisor flipbook, a client booklet and a self-help
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calendar for ST users. The delivery of BISCA is structured into pre-quit, quit and post-quit sessions which
are delivered by trained cessation advisors. The flipbook resource contains a set of slides presenting a set
of scenarios and incorporating photographs for advisors to initiate contact and dialogue with participants.
The client pack, a take-home resource given to participants, comprises the client booklet and an 8-week,
self-help calendar. The client booklet reinforces the key
messages delivered in the face-to-face session while
the calendar prompts participants to self-monitor and
record their ST use over time.
The participants receiving BISCA will be scheduled
for an initial (pre-quit) contact session on the day of
randomisation or on another convenient day in the
same week. Activities delivered in this session focus
on building knowledge around the ST ingredients and
harms related to ST use, building self-efficacy and
preparing participants for making a quit attempt. The
participants will receive one pre-quit session prior to
the quit date; however, those who are unable to proceed with a quit attempt will be eligible to receive an
additional pre-quit session.
The quit session will be scheduled in the week of the
participants’ quit date (either on the same day or 2–3
days preceding the quit date). Each participant will
receive one quit session which will focus on strengthening their ex-user identity, identifying triggers and
withdrawal symptoms and discussing strategies to
manage these. They will also be provided with a selfhelp calendar on this day for monitoring progress and
setting self-incentives.
After the quit session, the participants will receive
six weekly post-quit sessions with their cessation advisor. These sessions will focus on the reinforcement of
key messages delivered in pre-quit and quit sessions,
as well as support in avoiding relapse and minimising
withdrawal effects.
The pre-quit session will be conducted at the recruitment centres, while the quit and post-quit sessions will
either be delivered at the same place or in participants’
homes. The sessions will be scheduled in advance, and
a reminder will be issued to participants ahead of the
visit. Those who are unable to attend or have to cancel
their scheduled visit will be rescheduled on a convenient date within the same week. A log of delivered sessions will be maintained by the advisors to record the
total number of contacts made with each participant.
The participants who report lapses on two consecutive weeks will receive no further post-quit sessions;
however, they will be provided VBA to plan and execute their next quit attempt. The participants who are
non-responsive to phone calls or home visits on three
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separate occasions will be considered as being lost to
follow-up and continuing their ST use.
Identification and screening of trial participants

The trial participants will be identified from health
facilities located in the respective study locations in
each country. These are two NGO-based primary
healthcare facilities in Mirpur/Pallabi (Bangladesh)
and two primary care clinics based in Essa Nagri (Karachi). The selected facilities were identified from a list
of primary care and general practices which, following assessment, were selected by country trial teams
for the feasibility of conducting research activities.
In Noida (India), eligible participants will be identified through health and well-being clinics that offer
general health promotion and screening services. In
order to maximise the identification and recruitment
of participants through each of these facilities, country
teams will undertake community mobilisation using a
range of techniques in catchment areas. These techniques include public announcements, distribution of
brochures and information leaflets, as well as the promotion of the trial at health facilities ahead of the trial
start. Participants seeking primary care or those selfreferring themselves to the health facilities following
community mobilisation will be screened for eligibility.
The screening process will be carried out by a research
officer, who will administer a screening checklist to
determine eligibility and a CO breath test to rule out
concomitant smoking. A daily log of screening activities will be maintained at each health facility which will
be used to record the number of individuals assessed
and their eligibility for the trial. For non-eligible individuals, the reasons for ineligibility will be recorded.
Recruitment of trial participants

Eligible individuals will be provided with an information
sheet detailing (a) the purpose of the trial and the study
procedures; (b) potential benefits and risks of participation; (c) data handling procedures for privacy and confidentiality; (d) participants rights, including the right to
discontinue participation at any time in the trial; and (e)
relevant contact details for those who wish to seek more
information or clarity on the study. They will be provided
sufficient time and opportunity to clarify their queries
with the research officer and to include their peers or
family members in consideration of trial participation.
An informed consent process will be followed during
recruitment. Eligible individuals will read the information sheet or have it read out to them if they are unable to
read. They will then be asked to sign the consent sheet or
alternatively provide a thumb impression to indicate their
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consent in the presence of an impartial witness. A copy of
the signed consent form will be provided to all trial participants for their records.
Randomisation and treatment allocation

A centrally prepared computer-generated randomisation sequence will be used to randomly allocate eligible
and consenting trial participants to interventions. The
sequence will be created using software R v3.4 [27] and
enable country-stratified, permuted block randomisation with varying block sizes to be carried out. Eligible participants will be assigned on an equal allocation
basis to one of the three interventions or usual care. We
will additionally stratify recruitment by health facilities
in Pakistan and Bangladesh. The intervention assignment codes will be shared directly with the respective
country trial coordinators.
The treatment allocation will be concealed in sealed
envelopes. For the recruitment of an eligible participant, the field-based research officer will place a phone
call to the country coordinating centre, where the country trial coordinator will generate a trial ID by running
the pre-specified code in an R file. Both the trial coordinator and the research officer will be unaware of the
treatment associated with each trial ID. Once the trial
ID has been provided, a concealed envelope with the
corresponding trial ID will be opened to reveal the participant’s allocation. As this is a pilot trial, the objective
is not to conceal to either participants or researchers an
allocation to a particular intervention. The above process will ensure, however, allocation concealment up
until the point of delivery.
Data collection and follow‑up procedure

After recruitment, enrolled trial participants will complete an interviewer-administered Case Report Form
(CRF) at baseline. Collected data will include participants’ socio-demographic and household information,
current tobacco use, mood and physical symptoms,
nicotine dependence, contact with health providers,
attempts to quit ST, motivation to quit ST and mediators of ST cessation. These assessments will also be
repeated at 6, 12 and 26 weeks following their quit date
(Table 2).
Health resource utilization and quality of life (using the
EQ-5D-3L instrument [28]) will be measured at baseline
and 26-week follow-up as part of a preliminary economic
assessment. Taking healthcare provider and patient perspectives, health resource use will include the costs of
delivering the specified intervention in each arm (including staff time, materials and logistics), any health service
use (including visits to a healthcare provider, primary or
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tertiary care facility) and any out-of-pocket costs (including travel costs, fees paid to healthcare providers and
costs of medicines including any smoking cessation pharmacotherapy bought over-the-counter).
Saliva samples for biochemical verification of tobacco
abstinence will be collected from all participants at baseline and those self-reporting abstinence to all forms of
tobacco at 12 and 26-week follow-ups. Self-reported continued NRT use at these follow-ups will delay the collection of a saliva sample until participants report its use as
discontinued. A CO breath test will also be administered
at these time points to these participants to rule out any
smoked tobacco use. The saliva samples from Bangladesh
and Pakistan will be transferred to a specialist laboratory
(ABS laboratories, York, UK) for biochemical analysis for
salivary cotinine while those collected in India will be
analysed locally through an accredited laboratory.
Outcomes

The following will data will be analysed to address the
primary (feasibility) objectives of the trial:
Recruitment, randomisation and retention

– Number of participants screened, eligible and successfully recruited into the trial, along with characteristics of non-consenting and ineligible participants.
– Total number of participants enrolled in the allocated
recruitment period and time to complete recruitment in each country.
– Retention of trial participants in their original trial
arms following randomisation and the proportion of
participants attending data collection follow-ups at 6,
12 and 26 weeks along with number and reasons for
dropping out.
Intervention delivery

– The proportion of participants attending the pre-quit
and post-quit sessions, the number of quit and postquit sessions conducted per participant.
– The proportion of trial participants receiving low
(4mg) vs high (6mg) dose NRT, the proportion of
participants retaining their medication charts and
demonstrating their adherence to NRT at follow-up
visits.

Siddiqui et al. Pilot and Feasibility Studies

(2022) 8:189

Page 7 of 12

Table 2 Schedule of research activities
Activity/
assessment

Stage of study
Study
member

Recruitment

Intervention

Follow-up

Preenrolment

Postenrolment

Pre-quit

Quit

Post-quit

6 weeks

12 weeks

26 weeks

Screening &
consent

Baseline /
randomisation

Pre-quit
session(s)
(BISCA)

Quit
session
(BISCA)

6 Weekly
BISCA
sessions

Follow-up 1 Follow-up 2 Follow-up 3

Screening
log

Research staff X

Eligibility
form

Research staff X

Informed
consent

Research staff X

Random
allocation

Research staff

X

Baseline CRF

Research staff

X

Health
resource use
Questionnaire

Research staff

X

X

Quality of life
assessment
(EQ-5D-5L)

Research staff

X

X

VBA for ST
cessation

Advisor

X

BISCA sessions

Advisor

Adverse/serious adverse
events
checklist

Research
staff/advisor

Follow up
CRF

Research staff

Salivary
cotinine
(biochemical
verification)

Research staff

CO assessment

Research staff X

Qualitative
interviews
for process
evaluation

Research staff

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

BISCA behavioural support intervention for smokeless tobacco cessation in adults, CRF case-report forms, CO carbon monoxide, ST smokeless tobacco, VBA very brief
advice

Data collection methods

– Proportion of completed baseline and follow-up
assessments in each arm
– Total number of participants eligible to provide saliva
samples at 12 and 26 weeks and number of trial participants successfully providing a saliva sample.

The following data will be collected and analysed to
address part of the secondary objectives, i.e. the identification of cessation outcomes for the main trial:
– A 7-day point prevalence of tobacco use (smoked
and smokeless) at 6 weeks, 12 weeks and 26 weeks
of follow-ups. At 26 weeks, the point prevalence will
be verified by CO breath test (<10ppm) and salivary
cotinine assessment (<15ng/ml).
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– Continuous abstinence to all forms of tobacco at 26
weeks post-quit date. This will be self-reported only,
as we did not attempt to validate abstinence every
week.
Other aspects of the secondary objectives such as
process evaluation and health economic procedures are
described in subsequent sections.
Sample size

We calculated the sample size in line with recommendations by Viechtbauer et al. [29], which state that the
sample size should be sufficiently large to capture at least
one incidence of a range of anticipated and unanticipated
outcome events. Assuming the probability of these outcome events to lie between 5 and 10%, we estimated at
least 60 participants in each country, using a confidence
level of 95%. We increased this number to 80 participants per country in order to have at least 20 participants
per trial arm and further inflated this figure by 10% to
account for potential loss to follow-up. In total, we thus
require 88 participants per country (22/trial arm) with a
combined total of 264 participants in Bangladesh, India
and Pakistan.
Statistical analysis

Descriptive data analyses will be performed to describe
participant characteristics, as well as to address the feasibility objectives identified above. Reporting will be done
for the overall sample and where relevant, stratified for
each country. Measures will include summary statistics
such as mean and standard deviation for continuous
variables and frequencies (absolute and relative) for categorical variables. We will estimate risk ratios and 95%
confidence intervals for the potential cessation-related
outcomes as a preliminary assessment of effect. No inferences however will be made based on these results. All
statistical analysis will be performed on STATA version
16 [30].
Process evaluation

The process evaluation will be informed by the Medical Research Council guidance [31]. This identifies three
components: implementation, mechanisms of impact
and context.
Implementation and context

One to 2 cessation advisors will be interviewed in each
country to explore their experiences of delivering the
BISCA and NRT interventions. The impact of factors
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such as the community environment and other social,
economic, cultural, environmental and political factors will be assessed. Fidelity to delivering the BISCA/
NRT interventions will be assessed using a fidelity index
adapted from the original BISCA study [18]. This will be
applied to audio-recordings of nine randomly selected
participants per country (3 per intervention arm, excluding those allocated to receive VBA) who have completed
their allocated intervention.
Mechanisms of impact

All participants will complete a short questionnaire at
6-week follow-up which will have some acceptability
questions on trial processes. The questionnaire will also
explore the engagement with BISCA and NRT intervention components, acceptability of the sessions and perceived benefits/dis-benefits. A purposive sample of 24
participants in each country (8 from each intervention
trial arm), a mix of men and women who have/have not
quit ST will be interviewed to explore key issues that
emerged in the questionnaire. Data on potential mediators (see Fig. 1) will be collected at all time points.
Interviews will be conducted using a topic guide and
digitally audio-recorded. The quantitative data from the
fidelity index and questionnaire will be analysed using
descriptive statistics. The qualitative data from the questionnaire will be analysed using content analysis [32],
while transcribed and translated interviews will be analysed using the Framework Approach [33]. Micorosoft
Excel will aid data handling. The integration of interview
findings with respective questionnaire data will be done
using a ‘triangulation protocol’ [34].
Health economics

The analysis of economic data will include a preliminary
assessment of the costs associated with implementing
BISCA (alone or in combination with NRT) and NRT
alone as well as a change in EQ-5D-3L scores between
the baseline and 26 weeks post-baseline. The overall
assessment will include a commentary on the suitability/
feasibility of an economic evaluation alongside a future
definitive trial.
Data management

Each country site will hold data in accordance with both
the UK (General Data Protection Regulation [35], Data
Protection Act 2018 [36] and any additional countryspecific requirements. Collected data will be identified
by a unique identification number (i.e. the Trial ID number) only. Study files will be stored in accordance with
UK Good Clinical Practice (GCP) guidelines [37]. The
collected data will be stored separately from the consent
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sheets to maintain the anonymity of data. Research staff
at the University of York will develop and maintain an
electronic database that will be used to enter data by
research staff in each participant country. The database
will be uploaded to a secure server provided by York
University IT services and accessible only to researchers directly involved in the study or by representatives
of the Trial Data Management and Ethics Committee in
the event of a study audit. Similarly, all audio files and
anonymised transcripts will be uploaded and kept secure
throughout the duration of the study. Paper versions of
study documents at the participating sites, the country
coordinating centers and the University of York will be
retained in a secure (locked when not in use) location,
during and after the trial has finished. All essential documents, including source documents, will be retained for a
minimum period of 5 years after study completion.
Trial monitoring procedures

Mechanisms for trial monitoring include collection and
reporting of adverse events, regular trial audits and safety
monitoring by an independent Data Management and
Ethics Committee (DMEC).
Adverse events

A standardised approach for adverse events will be followed for their identification, recording and reporting.
Checklists will be completed each week, either faceto-face or via a phone call, to assess the frequency and
severity of Adverse (AEs) and Severe Adverse Events
(SAEs). All participants will also have access to a central number to report any sudden onset AEs. Reported
AEs will be assessed by the country trial coordinator for
seriousness, severity and relatedness to the intervention.
AEs related to the intervention will also be assessed for
their expectedness. Those with the potential to become
SAEs will be monitored till resolution. SAEs which are
related to the intervention will be reported to the DMEC
and Trial Steering committee within 3 days and the local
Ethics Committees within 15 days. The participants who
experience serious unexpected AEs related to the intervention will be withdrawn from treatment but will continue to be followed up in their respective trial arm.
Trial audit

Trial coordinators in each country will carry out regular
monthly audits, using monitoring checklists, to ensure
all staff are complying with standard operating protocols (SOPs) for implementation of all trial procedures
and that appropriate documentation is held at each trial
site. In addition, a lead investigator will make at least one
planned visit to each country’s coordinating centre during recruitment and follow-up. Additional unplanned
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visits by the trial coordinators may also be triggered if
specific concerns are raised by the trial management
team in order to address any potential issues around
data queries, compliance with the trial procedures or any
other logistic issues at trial sites.
Data monitoring and ethics

An independent DMEC, consisting of an independent
trial statistician and two subject experts, will oversee
progress in recruitment, safeguard the interests of trial
participants, assess the safety and futility of the interventions during the trial and monitor the overall conduct of
the trial. The DMEC will convene around recruitment
milestones and will provide recommendations and advice
to the Trial Steering Committee and Trial Sponsor on the
basis of submitted reports. Possible recommendations
include the following:
1) No action is needed, the trial continues as planned.
2) Early stopping due, for example, to clear harm of
treatment, futility or external evidence.
3) Extending recruitment activity to additional sites in
countries with low recruitment.
4) Stopping or suggesting a modification to any arm of
the trial.
5) Sanctioning and/or proposing protocol changes in
line with patient safety.

Dissemination of results

The trial results will be relevant to a wide range of academic audiences interested in tobacco cessation in
low- and middle-income countries. These include (i)
academics, (ii) clinicians, (iii) graduate and post-graduate students, (iv) health economists and (v) researchers
working in behavioural sciences, tobacco control and
global public health. The primary means of dissemination
to these audiences will be the publication of trial findings in open-access scientific journals. Each manuscript
will be developed in line with ASTRA’s publication policy, which also defines authorship criteria based on the
ICMJE guidelines [38] and entered into ASTRA’s publication log maintained at the University of York. In addition,
the results will be disseminated at international conferences and seminars on tobacco, oral health, cancer and
non-communicable diseases.
Non-academic audiences include two groups. The first
group includes people directly involved in research, i.e.
research participants, their families and community
stakeholders (residents, local administration, health
workers working in the respective communities). A
dissemination workshop will be organised for these
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audiences at the end of the trial highlighting key findings and results. The second group includes a wider
group of stakeholders—the general public, physicians,
policymakers, tobacco control advocates and non-governmental organisations. In each country, stakeholder
forums including these groups have been established as
part of ASTRA’s objectives. We will communicate trial
findings to these stakeholders in planned annual meetings. Besides these avenues, dissemination will also
be carried out through electronic, print and/or social
media on events such as World No Tobacco Day and
World Cancer Day. Findings will also be shared through
social media platforms (ASTRA Twitter account @
ASTRA_NIHR), the University of York ASTRA webpage (https://www.york.ac.uk/healthsciences/research/
public-health/projects/astra/), as well as through webpages of ASTRA’s partner institutions and Global health
groups such as RESPIRE [39, 40].

Discussion
The ASTRA feasibility study responds to the urgent need
to identify culturally suitable, evidence-based interventions for supporting successful quit attempts among ST
users in the South Asian region. Ongoing evaluation and
broader future implementation of such interventions is
highly likely to yield health-related and economic benefits to both ST users and the wider society.
Our approach proposes a combination of two evidencebased interventions, implemented using a robust study
design and validated outcome measures. The primary focus
of this present study on feasibility will identify implementation-related issues of relevance to developing the main trial.
These may include a general reluctance towards participation, collection of saliva samples and potential for loss to
follow-up due to participant migration/dispersion. The secondary focus on effectiveness will make a contribution to
the developing evidence base on ST cessation, particularly
in the South Asian region. The small sample size compromises the assessment of effectiveness in this study, which is
a natural limitation of feasibility trials. Another limitation
may be the long-term availability and provision of pharmacotherapy which is essentially an ‘out-of-pocket’ expense
in the South Asian region. This financial barrier has to be
addressed through ASTRA policy-oriented initiatives.
Protocol amendments

The current version of the trial protocol (version 1.2.1
dated on 21 February 2020) incorporates changes recommended by the trial sponsor and the Trial Management Team to date (supplementary file 1—protocol
amendments). All amendments to the protocol are first
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discussed with the Lead Investigator and then submitted to the Research Governance Committee for formal approval. A judgement is made on the nature of the
amendment, i.e. major or minor, applying guidance from
the University of York Research Governance Committee. All minor amendments are implemented once notified, while all major amendments are implemented once
approved by the respective national ethics committees in
each country.

Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s40814-022-01146-5.
Additional file 1. SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents.
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